G Skowron1, J C Street, E M Obee. 1. Roger Williams Medical Center/Boston University, Providence, Rhode Island 02908, USA. Gail_skowron@brown.edu
Abstract
OBJECTIVE: To investigate the relationship between viral load suppression and baseline viral load as well as that between viral load suppression and baseline CD4(+) cell count. DESIGN: Meta-analysis of published and presented studies. METHODS: Trials of two nucleoside analogs plus nevirapine, indinavir, nelfinavir, or efavirenz as therapy for antiretroviral treatment-naive patients with HIV infection or AIDS who were followed-up for at least 6 months were included in the meta-analysis. The proportion of patients with viral loads of <200-500 copies/ml at 6 and 12 months (total number of patients, 1619 and 761, respectively) was regressed to the mean or median baseline viral load and CD4(+) cell count. RESULTS: Thirty-six treatment arms from 30 studies were identified. Multivariate regression demonstrated a significant correlation between baseline CD4(+) cell count and virologic suppression at 6 and 12 months ( t = 2.85, p =.008; and t = 3.08, p =.010, respectively) but not between baseline viral load and virologic suppression ( t = 0.92, p =.365; and t = 1.31, p =.215, respectively). The same pattern was seen in a subanalysis of trials of nevirapine-containing therapy (CD4(+) cell count: t = 2.89, p =.014 at 6 months; viral load suppression: t = 0.84, p =.415). CONCLUSIONS: Baseline CD4(+) cell count was a better predictor of virologic suppression induced by triple combination therapy than was baseline viral load.
OBJECTIVE: To investigate the relationship between viral load suppression and baseline viral load as well as that between viral load suppression and baseline CD4(+) cell count. DESIGN: Meta-analysis of published and presented studies. METHODS: Trials of two nucleoside analogs plus nevirapine, indinavir, nelfinavir, or efavirenz as therapy for antiretroviral treatment-naive patients with HIV infection or AIDS who were followed-up for at least 6 months were included in the meta-analysis. The proportion of patients with viral loads of <200-500 copies/ml at 6 and 12 months (total number of patients, 1619 and 761, respectively) was regressed to the mean or median baseline viral load and CD4(+) cell count. RESULTS: Thirty-six treatment arms from 30 studies were identified. Multivariate regression demonstrated a significant correlation between baseline CD4(+) cell count and virologic suppression at 6 and 12 months ( t = 2.85, p =.008; and t = 3.08, p =.010, respectively) but not between baseline viral load and virologic suppression ( t = 0.92, p =.365; and t = 1.31, p =.215, respectively). The same pattern was seen in a subanalysis of trials of nevirapine-containing therapy (CD4(+) cell count: t = 2.89, p =.014 at 6 months; viral load suppression: t = 0.84, p =.415). CONCLUSIONS: Baseline CD4(+) cell count was a better predictor of virologic suppression induced by triple combination therapy than was baseline viral load.
Authors: Lisa M Frenkel; Yang Wang; Gerald H Learn; Jennifer L McKernan; Giovanina M Ellis; Kathleen M Mohan; Sarah E Holte; Shannon M De Vange; Diane M Pawluk; Ann J Melvin; Paul F Lewis; Laura M Heath; Ingrid A Beck; Madhumita Mahalanabis; Wilscott E Naugler; Nicole H Tobin; James I Mullins Journal: J Virol Date: 2003-05 Impact factor: 5.103
Authors: Putu Duff; Kate Shannon; Melissa Braschel; Flo Ranville; Mary Kestler; Ruth Elwood Martin; Andrea Krüsi; Kathleen Deering Journal: Int J STD AIDS Date: 2020-12-08 Impact factor: 1.359
Authors: Edson José Monteiro Bello; Amabel Fernandes Correia; José Ricardo Pio Marins; Edgar Merchan-Hamann; Luis Isamu Barros Kanzaki Journal: Drug Target Insights Date: 2011-11-24
Authors: Henry D Meriki; Kukwah A Tufon; Mbunkah H Afegenwi; Bernard A Nyindem; Pascal N Atanga; Damian N Anong; Fidelis Cho-Ngwa; Theresa Nkuo-Akenji Journal: Infect Dis Poverty Date: 2014-01-30 Impact factor: 4.520